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Background and aims 
Gastric cancer is a highly malignant disease and one of the leading causes of cancer-
related mortality worldwide. The course of the disease can vary, making the accurate 
prediction of its progression difficult. New biomarkers could help us assess cancer 
aggressiveness and behavior, which would be of value when evaluating the 
prognosis of each individual patient with gastric cancer. Podocalyxin-like protein 
(PODXL) is a cell-adhesion glycoprotein associated with an aggressive tumor 
phenotype and a poor prognosis in several forms of cancer. Prospero homeobox 
protein 1 (PROX1) is a transcription factor involved in the development of various 
organs, and also plays an important role in colorectal cancer progression. Ubiquitin 
carboxyl-terminal hydrolase L5 (UCHL5) is a cysteine protease being a part of the 
protein homeostasis network, and is found both in healthy and in cancer tissue. 
Matrix metalloproteinase-8 (MMP-8) belongs to the collagenase subgroup of MMPs 
and is capable of degrading the extracellular matrix (ECM). MMP-8 participates in 
the proteolytic processing of inflammatory mediators in a wide variety of biological 
processes and is also associated with various diseases including cancer. Tissue 
inhibitor of metalloproteinase-1 (TIMP-1) is an important regulator of MMPs and 
the extracellular environment. The aim of this study was to evaluate the expression 
and prognostic value of these potential biomarkers in gastric cancer. 
 
Materials and methods 
A total of 650 gastric cancer patients underwent surgery at the Department of 
Surgery, Helsinki University Hospital, between 1983 and 2009 were included in this 
study. Survival data and death-causes came from patient records, the Population 
Register Centre of Finland, and Statistics Finland. Two separate tissue microarray 
(TMA) series prepared from tumor tissue specimens from these patients were the 
material for immunohistochemical staining of studied antibodies. PODXL 
immunostaining was studied in TMA series of 337 samples. TMA series of 313 
samples were utilized in immunohistochemistry of PROX1 and MMP-8. UCHL5 
staining was studied in TMA series of 650 samples. The expression of these markers 
were evaluated and compared to clinicopathological variables and patient survival. 
From preoperative blood samples from 233 patients, serum levels of MMP-8 
underwent determination with an immunofluorometric assay (IFMA) and TIMP-1 
with enzyme-linked immunosorbent assay (ELISA). 
 
Results 
PODXL positivity indicated impaired gastric cancer-specific 5-year survival 
compared to that of patients with PODXL negativity. The result in multivariable 
analysis remained significant. Patients with high PROX1 expression had 
significantly better cancer-specific 5-year survival than did those with low 
expression, a result that remained significant in multivariable analysis. Patients with 
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positive cytoplasmic UCHL5 tumor expression showed increased survival in the 
subgroups of small (<5 cm) tumors, of disease stages I-II, and of age over 66. 
Patients with low (<31 ng/ml) or high (>131 ng/ml) serum MMP-8 level had an 
unfavorable prognosis compared to those with an intermediate (31-131 ng/ml) serum 
level. Those patients with high (≥170 ng/ml) serum TIMP-1 levels also had a poor 
prognosis, and the latter remained significant in multivariable analysis. The molar 
ratio of serum MMP-8 and TIMP-1 levels with low (<0.07) or high (>0.30) molar 
ratios predicted a worse prognosis. The prognosis remained the same despite of 
MMP-8 tissue immunoreactivity. 
 
Conclusions 
In gastric cancer tissue, positive PODXL expression is an independent marker of 
poor prognosis, high cytoplasmic PROX1 expression is an independent marker of 
better prognosis, and positive cytoplasmic UCHL5 is linked to better prognosis in 
certain subgroups. For prediction of prognosis in gastric cancer, serum MMP-8 and 
TIMP-1 are promising biomarkers. 
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3 TIIVISTELMÄ (FINNISH ABSTRACT) 
Taustat ja tavoitteet 
Mahasyöpä on maailmanlaajuisesti merkittävä syöpäkuolleisuuden aiheuttaja. 
Taudin kulku vaihtelee sen asteesta riippuen ja ennusteen määrittäminen 
yksilöllisesti voi olla vaikeaa. Uudet biomarkkerit saattaisivat auttaa syövän 
potilaskohtaisen vaikeusasteen ja käyttäytymisen ennustamisessa. Podocalyxin-like 
protein (PODXL) on solukalvon glykoproteiini. Aikaisemmissa tutkimuksissa sen on 
osoitettu liittyvän aggressiivisiin syöpäkasvaimiin sekä muutamissa syöpätyypeissä 
myös huonoon ennusteeseen. Prospero homeobox protein 1 (PROX1) säätelee solun 
perimän kopiointia eli transkriptiota. PROX1-proteiinilla on merkittävä rooli eri 
elinten kehityksessä, mutta sen on havaittu myös osallistuvan ainakin 
paksusuolisyövän kehittymiseen. Ubiquitin carboxyl-terminal hydrolase L5 
(UCHL5), solun proteiinien hajotusjärjestelmän entsyymi, liittyy solujen 
proteiinitasapainon ylläpitämiseen poistamalla ubikitiinia proteasomisubstraateista. 
Terveen kudoksen lisäksi sitä on löydetty myös vaihtelevia määriä syöpäkudoksista. 
Matrix metalloproteinase-8 (MMP-8), eli soluväliaineen endopeptidaasi, kuuluu 
soluväliaineen proteiineja hajottaviin entsyymeihin. Soluväliaineen tuhoamisen 
lisäksi sen on osoitettu säätelevän tulehduksellisia tekijöitä useissa tautiprosesseissa 
sekä myös syövässä. Tissue inhibitor of metalloproteinase-1 (TIMP-1) estää 
metalloproteinaasien toimintaa soluväliaineessa. Väitöskirjatutkimuksen tavoitteena 
oli selvittää näiden uusien biomarkkerien esiintymistä mahasyövässä sekä niiden 
mahdollista yhteyttä potilaiden ennusteeseen. 
 
Materiaali ja menetelmät 
Aineisto käsittää 650 Helsingin seudun yliopistollisessa keskussairaalassa (HYKS) 
vuosien 1983 ja 2009 välisenä aikana leikattua mahasyöpäpotilasta. Potilaiden 
elossaolo- ja kuolinsyytiedot on kerätty potilaskertomuksista, 
Väestörekisterikeskuksesta sekä Tilastokeskuksesta. Kudossirublokkitekniikassa 
kootaan useita kudosnäytteitä samalle kudosblokille. Potilaiden 
syöpäkudosnäytteistä valmistettiin kaksi sarjaa, joita hyödynnettin värjäämällä niitä 
tutkittujen biomarkkerien vasta-aineilla. Vasta-aineiden ilmentymä arvioitiin ja 
tuloksia verrattiin tiedossa olleisiin kliinispatologisiin muuttujiin sekä potilaiden 
ennusteeseen. Neljännessä osatyössä määritettiin myös 233 potilaan verinäytteistä 
MMP-8:n seerumipitoisuus immunofluorometric assay (IFMA)-menetelmällä sekä 




Mahasyöpäkudoksen positiivinen PODXL-värjäytyvyys ennusti potilaideiden 
heikompaa 5-vuotiselossaoloennustetta verrattuna potilaisiin, joiden PODXL-värjäys 
jäi negatiiviseksi. Tulos osoittautui merkitseväksi myös monimuuttuja-analyysissä. 
Kohtalainen tai voimakas PROX1-värjäytyvyys ennusti potilaille merkittävästi 
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parempaa 5-vuotiselossaoloennustetta verrattuna potilaisiin joiden 
värjäysvoimakkuus oli heikko tai negatiivinen ja myös tämä tulos osoittautui 
tilastollisesti merkitseväksi monimuuttuja-analyysissä. Syöpäsolujen sytoplasman 
positiivinen UCHL5-värjäytyvyys liittyi parempaan ennusteeseen potilailla joilla oli 
pieni kasvainkoko (<5 cm), I-II asteen syöpä tai jotka olivat yli 65-vuotiaita. Mikäli 
seerumin MMP-8-pitoisuus oli matala (<31 ng/ml) tai korkea (>131 ng/ml), ennusti 
se potilaiden huonompaa ennustetta. Potilailla, joilla oli korkea TIMP-1-
seerumipitoisuus (≥170 ng/ml), oli myös huonompi ennuste ja tämä tulos osoittautui 
merkitseväksi myös monimuuttuja-analyysissä. Syöpäkudoksen MMP-8-
värjäytyvyydellä ei ollut yhteyttä potilaiden ennusteeseen.  
 
Johtopäätökset 
Positiivinen PODXL-värjäytyvyys potilaan syöpäkudoksessa on itsenäinen huonon 
ennusteen merkki mahasyövässä. Sen sijaan selkeä sytoplasminen PROX1-
värjäytyvyys syöpäkudoksessa liittyy potilaan parempaan ennusteeseen. Positiivinen 
sytoplasman UCHL5-värjäytyvyys liittyy potilaiden parempaan ennusteeseen 
tietyissä alaryhmissä. Seerumin MMP-8 ja TIMP-1 ovat myös lupaavia 




AJCC American Joint Committee on Cancer 
CA Carbohydrate antigen 
CEA Carcinoembryonic antigen 
CI Confidence interval 
CIN Chromosomal instability 
CSS Cancer-specific survival 
CT Computed tomography 
DUB Deubiquitinating enzyme 
EBV Epstein-Barr virus 
ECM Extracellular matrix 
EGC Early gastric cancer 
EGD Esophagogastroduodenoscopy 
EGJ Esophagogastric junction 
ELISA Enzyme-linked immunosorbent assay 
EMR Endoscopic mucosal resection 
EMT Epithelial-to-mesenchymal transition 
ESD Endoscopic submucosal dissection 
EUS Endoscopic ultrasound 
GS Genomic stability 
HDGC Hereditary diffuse gastric cancer 
H&E Hematoxylin and eosin 
HER2 Human epidermal growth factor receptor 2 
HIPEC Hyperthermic intraperitoneal chemotherapy 
H. pylori Helicobacter pylori 
HR Hazard ratio 
IARC International Agency for Research on Cancer 
IFMA Immunofluorometric assay 
IQR Interquartile range 
miRNA MicroRNA 
MMP-8 Matrix metalloproteinase-8 
MRI Magnetic resonance imaging 
MSI Microsatellite instability 
PET Positron emission tomography 
PODXL Podocalyxin-like protein 
PROX1 Prospero homeobox protein 1 
ROC Receiver-operating characteristic 
TCGA The Cancer Genome Atlas 
TGF-β Transforming growth factor-β 
TIMP-1 Tissue inhibitor of metalloproteinase-1 
TMA Tissue microarray 
TNM Tumor, node, metastasis 
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UCHL5 Ubiquitin carboxyl-terminal hydrolase L5 
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UICC Union for International Cancer Control 




Cancer is a leading cause of death worldwide, and the number of new cancer cases 
and deaths is estimated to rapidly increase as the populations grow and live longer 
and at the same time adopt lifestyle behaviors that increase cancer risk. Globally, 
gastric cancer is the fifth most common cancer and the third leading cause of cancer-
related deaths. Its geographic and socioeconomic diversity of incidence is 
considerable: about 70% of gastric cancer cases occur in developing countries and 
about half in eastern Asia (Torre 2015). In Finland, gastric cancer is rare nowadays 
being responsible of about 2% of all cancers and about 4% of cancer-related deaths 
(Finnish Cancer Registry). 
 
The incidence and mortality rates of gastric cancer have been substantially declining 
during recent decades. These changes are assumed to be attributable to the declining 
prevalence of Helicobacter pylori infection due to improved sanitation and 
antibiotics, better availability of fresh food with less reliance on salt-preserved food 
(Parkin 2006). Decline in tobacco smoking in developed countries may also have 
contributed to the fall in gastric cancer rates (Ladeiras-Lopes 2008, Bertuccio 2009). 
 
Despite developments in incidence, diagnostics, and therapeutic options in recent 
decades, the gastric cancer prognosis still remains poor, especially at advanced 
stages. The basis of curative treatment is radical surgery. The prognosis is highly 
TNM-stage-specific with 5-year survival of 57–71% for stage I disease, 33-46% for 
stage II, 9-20% for stage III, and 5-year survival falls to only 4% for stage IV 
patients (Edge 2010). Regardless of the new treatment options such as surgery 
combined with perioperative chemotherapy, gastric cancer remains very difficult to 
control and to cure. Undoubtedly the need is to identify biomarkers that can help to 
improve the individual patient’s prognosis, and thereby improve choice of the best 
treatment options. 
 
Gastric cancer is not a single disease, it is now clear that it is multifactorial and 
highly molecularly diverse. Recently, The Cancer Genome Atlas has described a 
new classification of four molecular subtypes of gastric cancer (Cancer Genome 
Atlas Research Network 2014). The subtypes are enriched for selected molecular 
abnormalities, potentially guiding patient stratification and targeting key pathways 
driving the tumor in each individual patient. 
 
Biomarkers, particularly tumor markers, may be useful in the early detection of 
tumors, in assessment of the extent of tumor growth or spread, or in identification of 
tumor recurrence. They are expressed by the tumor itself or by the host in response 
to the tumor. Tumor markers may be reactive molecules detected from bodily fluids 
or tissues and ideally should be both sensitive and specific for the detection of 
cancer, with a methodology sufficient simple and cost-effective; they should identify 
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tumor recurrence after treatment and help to determine prognosis and an individual 
treatment plan for each cancer patient. 
 
This thesis consists of studies on a set of novel, promising prognostic biomarkers in 
gastric cancer. The project includes immunohistochemical tumor tissue studies of 
podocalyxin-like protein (PODXL), prospero homeobox protein 1 (PROX1), 
ubiquitin carboxyl-terminal hydrolase L5 (UCHL5), and matrix metalloproteinase-8 
(MMP-8), as well as detection of preoperative serum levels of MMP-8 and tissue 
inhibitor of metalloproteinase-1 (TIMP-1), in association with different 




6 REVIEW OF THE LITERATURE 
6.1 Epidemiology and incidence 
The first documented cases of possible gastric cancer date back to 1600 BC when 
they were described in the Ebers Papyrus; later reports of Hippocrates included the 
words “cancer” and “carcinoma” for the very first time, but he believed that cancer 
was something attacking the human body from outside and penetrating through the 
skin to the internal organs. Much later, in 1881, Theodor Billroth performed the first 
successful gastric cancer operation, a subtotal resection with gastroduodenal 
anastomosis in Vienna (Santoro 2005). 
 
Nowadays gastric cancer is the world’s fifth most common cancer type, with 
952 000 new cases (6.8% of the total) and an age-adjusted incidence of 17.4/100 000 
in men and 7.5/100 000 in women in 2012 (Ferlay 2014). The incidence has 
decreased dramatically in recent decades, especially in the Western and more 
developed world, since the era when it was the most common cancer worldwide, 
around 1975. Still, incidence rates vary widely across different countries. The 
highest incidences occur in men in eastern Asia (China, Japan, Korea) with up to 69 
cases per 100 000 (Yamaoka 2008). Incidence rates are also high in central and 
eastern Europe, and in South America. Rates are lowest in North America and most 
parts of Africa (Torre 2015). 
 
Worldwide, gastric cancer is the third most common cause of cancer-related death, 
with approximately 723 000 deaths (8.8% of the total) in 2012. Mortality rates are 
highest in eastern Asia (24/100 000 in men and 9.8/100 000 in women) and lowest in 
North America (2.8 and 1.5 respectively). Mortality rates are also high in eastern and 
central Europe, and in central and South America (Torre 2015). 
 
In Finland, according to the Finnish Cancer Registry, the number of new gastric 
cancer cases has decreased considerably in recent decades. In 2015, new cases 
numbered 600, and gastric cancer age-adjusted incidence was 6.5/100 000 for men, 
3.8/100 000 for women (Figure 1). The age-standardized 5-year survival of gastric 
cancer was 24% for men, 29% for women. In 2015, Finland had a total of 453 gastric 
cancer deaths (3.42/100 000). 
 
Gastric cancer incidence increases with age, with the peak occurring at age 60-80. 
Among those under 30, gastric cancer is very rare (Theuer 1996, Nakamura 1999). 
The age-adjusted incidence rate is about twice as high among men as among women 
(Hartgrink 2009, Torre 2015). Nowadays, the overall number of distal tumors is 
declining at the same time as more proximal tumors are becoming more frequent, 
possibly linking the etiology of different tumors with their anatomic location. 
Increased rates of gastroesophageal reflux and overweight may play a role in the 
20 
rising incidence of more proximal gastric tumors, although no evidence exists of any 






Figure 1. Gastric cancer, pancreatic cancer, and the present (2014) three most common cancer-
site age-adjusted incidence in Finland for A) men and B) women. Adapted from the Finnish 
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6.2 Etiology and risk factors 
6.2.1 Helicobacter pylori 
Australian scientists Barry Marshall and Robin Warren identified the gram-negative 
bacterium Helicobacter pylori and its presence in a person with chronic gastritis and 
gastric ulcers, in 1982 (Marshall 1984). In recognition of their discovery, they 
received the 2005 Nobel Prize in Physiology or Medicine. Strong evidence from 
various epidemiological and prospective studies has shown that long-term H. pylori 
infection is closely linked to development of atrophic gastritis, which may induce 
intestinal metaplasia, dysplasia, and gastric cancer (Helicobacter and Cancer 
Collaborative Group 2001, Uemura 2001, Correa 2007). Atrophic gastritis and 
intestinal metaplasia then raise the relative risk for development of gastric cancer, 
ranging from 1.7 in moderate atrophy and 4.9 in severe atrophy, to 6.4 in intestinal 
metaplasia (Uemura 2001). H. pylori infection has been classified by the 
International Agency for Research on Cancer (IARC) as a type-I carcinogen in 
gastric cancer (The Eurogast Study Group 1993). The risk for gastric cancer is 
approximately six-fold higher in populations with 100% H. pylori infection than in 
populations without any infection (Helicobacter and Cancer Collaborative Group 
2001). Still, among H. pylori-infected individuals only approximately 10% develop 
gastric ulcer, and only 1-3% gastric cancer (Wang 2014). In addition, differences in 
H. pylori cagA and vacA genotypes may explain geographical variations: why some 
populations have high rates of H. pylori infection but low incidences of gastric 
cancer, such as Africa and South Asia (Yamaoka 2008). 
6.2.2 Epstein-Barr virus 
The other microbe associated with gastric cancer, Epstein-Barr virus (EBV), is one 
of the most common viruses in humans and best known as the cause of 
mononucleosis. It is present in gastric-cancer tumor cells at a rate of approximately 
9% of gastric cancers (Murphy 2009). Patients with EBV-positive cancer show a 
better outcome than do those with EBV-negative tumors (Camargo 2014). The 
mechanisms underlying this association are unclear, with several theories trying to 
explain it. A potential immunological basis could exist, in which cytotoxic CD8 
lymphocytes may promote eradication of EBV-positive malignant cells (Saiki 1996). 
An alternative hypothesis is that genetic alterations potentially associated with better 
survival may be more common in EBV-positive tumors (Wang 2011). 
6.2.3 Hereditary syndromes 
About 10% of gastric cancers exhibit familial clustering, but only a small number, 
only 1% to 3%, result from inherited syndromes (Oliveira 2004, Lynch 2005). 
Hereditary diffuse gastric cancer (HDGC) is a rare and autosomal-dominant 
inherited form of gastric cancer which typically develops at a young age (Kaurah 
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2007). HDGC is characterized by a highly invasive diffuse-type tumor, delayed 
presentation, and poor prognosis. HDGC represents a prominent molecular 
abnormality with defective intercellular adhesions which may be the result of loss of 
expression of the cell adhesion protein E-cadherin (Guilford 1998, Richards 1999, 
Oliveira 2009). Approximately one-quarter of families with HDGC have an 
inactivating E-cadherin gene (CDH1) germline mutations. Estimated lifetime gastric 
cancer risk in CDH1 carriers is in men, 67%, in women, 83%. The guidelines 
recommend CDH1 testing for 1) families with two or more patients with gastric 
cancer at any age with one confirmed diffuse cancer type, 2) individuals with diffuse 
gastric cancer before the age of 40, and 3) families with both diffuse gastric cancer 
and lobular breast cancer (one diagnosis before the age of 50) (van der Post 2015). 
Other hereditary syndromes linked to gastric cancer are familial adenomatous 
polyposis, Lynch syndrome, juvenile polyposis syndrome, Peutz-Jeghers syndrome, 
Li-Fraumeni syndrome, and gastric hyperplastic polyposis (Varley 1995, Vasen 
1996, Keller 1998, Shinmura 2005, Gylling 2007). 
6.2.4 Dietary and lifestyle factors 
Populations with diets rich in salted and smoked food containing nitrates and nitrites, 
rich in starch, and with no fresh fruits and vegetables, are at higher risk for gastric 
cancer. A diet like this may have an effect on acid-catalyzed nitrosation in the 
stomach and thus cause mechanical damage to the gastric mucosa (Ramón 1993, 
Tsugane 2007, Krejs 2010, Berretta 2012). In addition, refrigerator use, fruit intake, 
and gastric cancer mortality have a negative association (Bae 2008, Park 2011). 
 
Smoking is also a reported risk factor for gastric cancer. In a meta-analysis covering 
42 articles, current smokers had a relative risk of 1.53 developing gastric cancer 
comparing to never-smokers (González 2003, Ladeiras-Lopes 2008). The association 
of alcohol consumption and gastric cancer has been investigated in numerous studies 
with inconsistent results. Some evidence exists that heavy alcohol drinking may 
associate with a modestly increased risk for gastric cancer (Duell 2011, Tramacere 
2012). Acetaldehyde is the first metabolite of ethanol oxidation and also the most 
carcinogenic compound of tobacco. It is classified as a carcinogen in humans 
(Secretan 2009). Aldehydedehydrogenase (ALDH2) and alcoholdehydrogenase 
(ADH) gene polymorphisms associating with alcohol drinkers enhanced 
acetaldehyde exposure cause increased cancer risk for gastric cancer (Salaspuro 
2011). 
6.2.5 Earlier gastric surgery 
 
Gastric cancer risk increases in the gastric stump after earlier distal gastrectomy, 
even though the reason for surgery has been benign, such as in peptic ulcer disease. 
The incidence of gastric-stump cancer is estimated at 1-2%, but no prognostic 
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differences have emerged between stump and primary gastric cancer (Stalnikowicz 
1990, Takeno 2014, Thorban 2000). 
6.3 Pathogenesis 
Intestinal-type gastric cancer develops through a sequence of precursor lesions: 
chronic gastritis, mucosal atrophy, intestinal metaplasia, dysplasia, and intestinal 
cancer (Correa 1992). These changes are induced by H. pylori infection (Forman 
1991, Parsonnet 1991). Five years after diagnosis, the annual incidence of gastric 
cancer is 0.1% for atrophic gastritis, 0.25% for intestinal metaplasia, 0.6% for mild-
to-moderate dysplasia, and 6% for severe dysplasia (de Vries 2008).  
 
Precursors of gastric cancer are gastric adenomas with dysplastic epithelial cells. 
They can be solitary and occur anywhere in the stomach, but are commonly located 
in the antrum. Histologically, adenomas are classified into tubular, villous, and 
tubulovillous types, and they may arise after a history of atrophic gastritis and 
intestinal metaplasia typically associated with H. pylori infection. The risk for cancer 
development in adenomatous polyps also increases with age and with lesion size. 
Gastric adenomas occur with similar frequency in men and women (Cristallini 1992, 
Goddard 2010, Shaib 2013). 
 
Gastric cancer arises as the result of accumulated genomic damage affecting cellular 
functions vital for cancer development. These hallmarks of cancer include sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, and activating invasion and 
metastasis (Hanahan 2000, 2011). These genomic changes may arise from two 
different genomic instability pathways: microsatellite instability or chromosomal 
instability (Lengauer 1998).  
 
About 15% of gastric cancers are associated with a defect in the mismatch repair 
system manifested as tumor microsatellite instability (MSI) (Bacani 2005). 
Throughout cell replication, this repair system notices base pair mismatches, which 
occur by addition or deletion of a base. Mismatch repair proteins excise the 
mismatched lesion and resynthesize the DNA before the cell cycle is ready. 
Silencing of mismatch repair proteins is the most frequent cause of microsatellite 
instability in sporadic gastric cancer, leading to increased mutation rate at the 
nucleotide stage (Fleisher 1999). This microsatellite instability has been associated 
with intestinal-type cancer, tumor location in the antrum, less frequent lymph node 
metastases, and better survival (Wu 2000, Beghelli 2006). 
 
Roughly 85% of sporadic gastric cancers show chromosomal instability. This 
manifests in numerical or structural changes of large parts of, or even whole 
chromosomes, with an aneuploidy DNA pattern. The underlying mechanism of 
chromosomal instability is largely unknown. Mitotic chromosomal missegregation 
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and spindle checkpoint errors have been considered (Aguilera 2008, Hartgrink 
2009). 
 
Preceding the development of invasive gastric cancer is a stepwise evolution through 
a cascade of precancerous lesions. Sequential histopathological changes occur in the 
gastric mucosa including atrophic gastritis with loss of parietal cell mass, intestinal 
metaplasia, and dysplasia, all of which eventually leads to cancer. This metaplasia-
dysplasia-carcinoma sequence is more relevant for the intestinal-type gastric cancer 
that develops by a cumulative series of genetic alterations similar to those in 
colorectal cancer (Correa 1992, 2012). 
6.4 Classifications 
Anatomically, the stomach is divided into several subsites: cardia, fundus, corpus, 
antrum, and pylorus. Cancers with a midpoint in the stomach situated more than 5 
cm distal to the esophagogastric junction (EGJ), or those within 5 cm from the EGJ 
but not extending into the EGJ or esophagus, are classified as gastric cancers (Sobin 
2009). The proximally situated cancers with a midpoint in the esophagus, EGJ, or 
cardia that extends into the EGJ or esophagus are classified as esophageal cancers. 
Anatomically, the medial and lateral curvatures are called the lesser and greater 
curvatures (Edge 2010). Histologically, the wall of the stomach has five layers: the 
mucosa, submucosa, muscularis propria, subserosa, and serosa. Approximately 95% 
of gastric tumors are epithelial in origin and classified as adenocarcinomas. 
Adenosquamous, squamous, and undifferentiated carcinomas are rare (Sarbia 2004).  
 
The Laurén classification stratifies gastric adenocarcinoma into two major histologic 
types: intestinal and diffuse, describing tumors on the basis of their microscopic 
configuration and growth pattern (Laurén 1965). Intestinal carcinoma form glands 
that range from well to poorly differentiated tumors and which grow in expanding 
patterns and typically arise from chronic atrophic gastritis and intestinal metaplasia 
(Dicken 2005). Diffuse carcinoma consists of noncohesive tumor cells diffusely 
infiltrating the gastric wall with little or no gland formation. These cells are usually 
round and small and may look like signet rings when mucus-containing cells push 
the nucleus to the cell periphery; they can be arranged as separate single cells or in 
clusters. Linitis plastica is a morphologic variant of diffuse cancer in which the 
gastric wall thickens without clear tumor borders. A mixed carcinoma is a tumor that 
contains approximately equal quantities of intestinal and diffuse components.  
 
These two histological types, intestinal and diffuse, differ in their histologic 
appearance but also differ in gender ratio, age at diagnosis, and other epidemiologic 
features (Henson 2004). The diffuse type gastric cancer is more often seen in women 
and young patients, and is typically situated in the proximal stomach (Laurén 1965). 
The intestinal type is more common in men and older patients. It tends to arise from 
precancerous lesions, it is often associated with intestinal metaplasia and H. pylori 
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infection, it is more often situated in the distal portion of the stomach, and it is linked 
to dietary factors (Kaneko 2001). 
 
The World Health Organization (WHO) classifies gastric adenocarcinoma as tubular, 
papillary, mucinous, and poorly cohesive, including signet ring cell carcinoma, and 
uncommon histologic variants (Hamilton 2000). Despite tumors’ histological 
variability, classification is based on the predominant histological pattern that often 
co-exists with less dominate elements of other histologic patterns. 
 
The Cancer Genome Atlas (TCGA) has suggested a new molecular subtyping of 
gastric adenocarcinomas into four subtypes based on the presence of Epstein-Barr 
virus (EBV), microsatellite instability (MSI), genomic stability (GS), and 
chromosomal instability (CIN) (Cancer Genome Atlas Research Network 2014, 
Figure 2). These subtypes have distinct genomic features, providing a guide for 
patient stratification and trials of targeted therapies. This kind of classification offers 
valuable information about the variability in biological characteristics among gastric 
cancer but is not applicable for routine clinical diagnostics. Recently, some more 
straightforward methods may be able to reveal more useful classifications for clinics 
(Kim 2016, Park 2016, Setia 2016, Ahn 2017, Birkman 2017). 
 
 
Figure 2. Key features of the new molecular subtyping of gastric adenocarcinoma by TCGA. 
Reprinted with permission of Springer Nature (Cancer Genome Atlas Research Network 2014). 
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6.5 Clinical manifestations and diagnosis 
6.5.1 Symptoms 
As early pathognomic symptoms are lacking, patients often already show advanced 
gastric cancer at diagnosis. Nonspecific early symptoms may be nausea, mild upper 
gastrointestinal distress or heartburn, flatulence, excessive belching, and abdominal 
pain or fullness after meals. Weight loss, vomiting, dysphagia, fatigue, 
gastrointestinal bleeding, and a palpable abdominal mass are usually signs of 
advanced cancer (Catalano 2009, Hartgrink 2009). Chronic anemia may correlate 
with ulcerated lesions. Distal tumors may cause obstructive symptoms, whereas 
proximal tumors typically manifest with nausea and vomiting (Dicken 2005).  
 
Metastatic manifestations may be liver enlargement, presence of ascites, jaundice, 
and palpable lymph nodes in the supraclavicular region (Virchow’s node), in the left 
axilla (Irish’s node), or in the periumbilical region (Sister Mary Joseph node). 
Peritoneal spread may cause ovarian metastases (Krukenberg tumor) or a palpable 
pelvic mass (Blumer’s shelf) (Dicken 2005, Catalano 2009). Paraneoplastic 
syndromes are rare, but include dermatomiositis, acantosis nigricans, 
microangiopathic hemolytic anemia, and chronic intravascular coagulation leading to 
arterial and venous thrombi (Trousseau’s syndrome) (Catalano 2009). 
6.5.2 Endoscopy 
Esophagogastroduodenoscopy (EGD) is the method of choice for gastric cancer 
diagnosis, as it allows direct visualization of tumor appearance, size, location, and 
the extent of mucosal involvement, and at the same time enables to photography and 
biopsies from suspected lesions (Dicken 2005). 
 
Endoscopic ultrasound (EUS) can help with tumor staging by providing information 
about depth of tumor invasion and allowing evaluation of perigastric 
lymphadenopathy (Willis 2000). EUS seems to be most effective method to 
differentiate stages T1 to T2 from stages T3 to T4 (Kwee 2007). 
6.5.3 Preoperative staging 
The presence of possible metastases determines treatment, and computed 
tomography (CT) is the most frequent modality for gastric cancer staging (Halvorsen 
1996, Angelelli 2001). CT can detect liver metastases and regional and distant 
lymphadenopathy, and can show signs of tumors’ direct invasion into adjacent 





For preoperative staging, what is vital to assess is whether the cancer is suitable for 
radical surgical resection. Even though improved imaging techniques enable staging 
more adequately than previously, CT alone is insufficiently sensitive to detect or 
exclude peritoneal metastases. In patients with gastric cancer, the sensitivity of CT to 
detect metastatic lymph nodes varies from 62.5% to 91.9% (Kwee 2009). Staging 
laparoscopy is an adjunct to imaging of patients being considered for curative 
surgery (Leake 2012, Burbidge 2013, Machairas 2017). Staging laparoscopy may 
change the surgical treatment plan even in 20 to 30% of cases, and may help to 
reduce perioperative mortality, eliminating nontherapeutic laparotomies (Smith 
2007, Coburn 2010, Shelat 2012).  
 
Magnetic resonance imaging (MRI), even though its accuracy in tumor staging is at 
least similar to that of CT, has limited use in the staging of the primary due to 
difficulties with motion artifact, cost, required time, and lack of an appropriate oral 
contrast agent (Sohn 2000, Motohara 2002). 
 
Positron emission tomography (PET), despite its ability to visualize areas of 
enhanced metabolic activity within tissues, has been assumed to have a low detection 
rate for diagnosis of primary gastric cancer, especially in its early stage and in 
gastric-cancer types that are less metabolically active. PET appears, however, to be 
more specific for detection of metastatic lymph nodes, peritoneal lesions, and bone 
metastases as compared to CT alone (Gauthé 2015, Malibari 2015, Kawanaka 2016). 
PET-CT is a modality that combines these two techniques. 
6.6 Treatment 
Treatment planning is always done individually and must take into account the stage 
of the disease, co-morbidities, performance status of the patient, and the patients’ 
own wishes and expectations. An algorithm of different treatment options is in 
Figure 3. Multidisciplinary treatment planning is the recommendation before any 
treatment decision. The multidisciplinary team should include surgeons, medical and 
radiation oncologists, radiologists, and pathologists (Smyth 2016). 
6.6.1 Surgery 
Surgery is the first-line therapy for curing gastric cancer. Subtotal gastrectomy is 
suitable for distal cancer if a macroscopic proximal margin of 5 cm can be achieved 
between the tumor and EGJ. For diffuse cancer, a margin of 8 cm is the 
recommendation. Otherwise, the choice is total gastrectomy. Evidence exists that 
both procedures, subtotal and total gastrectomy, show similar survival and mortality 
rates. Subtotal gastrectomy, associated with better nutritional status and quality of 
life, should be the procedure of choice, provided that the proximal margin of the 



















The extent of gastric resection has classically been described based on the proximity 
of the dissected lymph nodes (Figure 4). D0 resection means no nodes are removed, 
and is typical in the case of palliative resection. In D1 resection, the perigastric 
nodes along the lesser and greater curvature are removed, together with the 
omentum. D2 dissection indicates the removal of nodal tissue along the left gastric, 
common hepatic, celiac, and splenic arteries. For D3 lymphadenectomy, nodes from 
the porta hepatis, the hepaticoduodenal ligament, and the periaortic and 
retropancreatic regions must be removed (Hartgrink 2009, Japanese Gastric Cancer 
Association 2011). 
 
The suitable extent of lymphadenectomy for curative surgery has been the subject of 
considerable debate over recent decades (Tanizawa 2010). It is conceivable that 
removal of a large number of lymph nodes improves survival. A limited number of 
randomized controlled trials from the Western world have focused on this issue. The 
first results of the prospective randomized Dutch trial comparing D1 with D2 
lymphadenectomy, indicated significantly higher mortality after a D2 dissection (10 
vs. 4%) (Bonenkamp 1995). At the same time, The Medical Research Council 
Gastric Cancer trial demonstrated that the number of splenectomies and 
pancreatectomies, which have been shown to increase postoperative mortality, were 
also higher in the D2 group than in the D1 group (Cuschieri 1996). Similarly, a 
recent Italian study failed to demonstrate any survival advantage with D2 dissection, 
although they suggested a trend towards a benefit from D2 resection in disease-
specific survival for patients with T2-T4 tumors with positive lymph nodes (Degiuli 
2014). After 11 and 15 years of follow-up, the Dutch study group revealed no 
significant differences in overall survival. However, when they analyzed cause-
specific survival at 15 years, gastric cancer-related death was significantly lower 
after D2 (37%) than after D1 (48%) dissection (p=0.01), suggesting that when 
postoperative mortality can be avoided, D2 lymphadenectomy improves survival 
after gastric cancer resection (Hartgrink 2004, Songun 2010). Hereby, D2 dissection 
for a medically fit patient in experienced, high-volume centers should be the 
recommended type of surgery in advanced, resectable gastric cancer (Dikken 2011, 
Smyth 2016).  Dissection more extended than D2 seem to have no survival benefit 
(Sasako 2008). 
 
Since 1991, laparoscopic surgery has been adopted for gastric cancer treatment, 
starting in Asian countries. In its early years, only early and distal cancers were 
treated by a laparoscopic method. However, as surgeons gained more experience, 
more extensive procedures become more common. Laparoscopic surgery seems to 
be associated with quicker return of gastrointestinal function, faster ambulation, 
earlier discharge from hospital, and has comparable complications and recurrence 
rate to those of open surgery. However, the length of operating time for laparoscopy 
remains longer (Shehzad 2007, Chen 2014). Discussion of adequate lymph node 
dissection with a laparoscopic approach involves evidence that lymph node 
dissection for both approaches is comparable (Quan 2016, Chen 2017).  
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In gastric cancer surgery, avoiding postoperative mortality is a challenge, especially 
when performed in countries with lower incidence, leading naturally to lower 
exposure of hospitals and surgeons to resectable gastric cancer cases. Many studies 
have analyzed the relation between hospital volume and outcome, and found that 
increased surgeon´s and hospital volumes are associated with lower postoperative 
mortality and higher survival rates, both in Western countries and in Asia (Begg 
1998, Birkmeyer 2002, Dikken 2011,2013). For example, in Denmark, gastric cancer 
surgery centralization has led to a significant decrease in postoperative mortality and 
an increase in the number of patients with at least 15 lymph nodes examined (Jensen 
2010). Centralization of gastric cancer surgery to five university hospitals is 
currently implemented also in Finland (Finnish Ministry of Social Affairs and 
Health, 2017). 
 
In locally advanced or metastatic disease, palliative resection of the primary tumor or 
its metastases is not recommended in general (Smyth 2016). The primary goal in 
palliation is relieving symptoms and improving quality of life. Regardless, 
sometimes surgery is still needed to relieve difficult symptoms such as bleeding or 
obstruction. Possible procedures for palliative surgery are resection without lymph 
node dissection, gastrojejunostomy or other by-pass procedures, or endoscopically 
applied self-expanding metallic stents. However, some uncontrolled case series do 
suggest better survival for selected patients undergoing resection of lung or liver 
metastases or surgical removal of Krukenberg tumors; currently surgery of 
metastases remains experimental, however, until further evidence (Shiono 2013, 
Rosa 2016, Markar 2017). Similarly, few Asian studies have proposed a notable 
survival benefit for adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in 
high-risk curatively resected gastric cancer patients (Fujimura 1994, Fujimoto 1999). 
Cytoreductive surgery together with HIPEC is also studied as a treatment for patients 
with advanced peritoneal metastases trying for a survival benefit (Glehen 2010, 
Yang 2011). Currently in Europe, HIPEC in treatment of gastric cancer is used only 
















Figure 4. Regional lymph nodes of the stomach: right (1) and left (2) paracardial nodes, 
perigastric nodes of the lesser (3) and the greater (4a, 4b) curvatures, suprapyloric (5) and 
infrapyloric (6) nodes, nodes along the left gastric (7), the common hepatic (8), and the celiac (9) 
arteries, nodes of splenic hilum (10), nodes along the splenic artery, and hepatoduodenal (12) 
nodes. Figure drawn by Marja Ojala. 
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6.6.2 Oncological treatment 
Surgeons have tried to improve the prognosis of gastric cancer by extending lymph 
node dissection in radical surgery, but without improved results. It is obvious that 
better survival can be achieved only by finding effective pre- and postoperative 
oncological modalities. 
 
The present European guidelines recommend perioperative (pre- and postoperative) 
chemotherapy with a platinum/fluoropyrimidine combination for patients with stage 
IB or advanced resectable gastric cancer (Smyth 2016). This recommendation is 
based on randomized trials. The MAGIC trial showed a survival benefit from 23% to 
36% in 5-year survival for patients treated with six cycles of perioperative 
chemotherapy (three pre- and three postoperative) in resectable stage II and III 
gastric cancer compared with surgery alone (Cunningham 2006). Another study has 
demonstrated a similar result, but a majority of the patients included, had proximal 
tumors, comprising cancers of the EGJ (Ychou 2011). 
 
If gastric cancer has been operated on directly without preoperative chemotherapy, 
and is stage IB or advanced, postoperative chemoradiotherapy or adjuvant 
chemotherapy is the recommendation (Smyth 2016). Earlier, postoperative 
chemoradiotherapy was standard treatment, based on a trial that showed improved 
overall survival benefit compared to that of surgery alone (Macdonald 2001, Smalley 
2012). Lack of adequate lymphadenectomy has inspired criticism of the trial, 
suggesting that the benefit of postoperative chemoradiotherapy may only 
compensate for this suboptimal surgery (Smyth 2016). The Dutch D1D2 trial also 
showed retrospectively that after D1 dissection, postoperative chemoradiotherapy 
improved survival, but not after optimal D2 resection (Dikken 2010). However, 
other studies also support postoperative chemoradiotherapy even after adequate 
surgery; this subject is under debate and requires further investigation (Kim 2005, 
Zhu 2012, Park 2015). The survival benefit of postoperative adjuvant chemotherapy 
has been demonstrated mainly in Asian studies (Sakuramoto 2007, Sasako 2011, 
Bang 2012, Noh 2014). A large, international meta-analysis of adjuvant 
chemotherapy confirmed a 6% benefit for chemotherapy compared with surgery 
alone (GASTRIC Group 2010).  
 
A notable number of gastric cancer patients are diagnosed with already inoperable 
locally advanced or metastatic disease. Chemotherapy is the treatment of choice for 
them if co-morbidities, organ function, and performance status allow (Smyth 2016). 
Chemotherapy has improved survival and quality of life compared with results from 
supportive care only (Glimelius 1997, Bouché 2004). About 10% to 15% of gastric 
cancers overexpress human epidermal growth factor receptor 2 (HER2). 
Trastuzumab, a monoclonal antibody against HER2, is recommended for those 
patients with advanced disease as a target treatment, in combination with 
chemotherapy, for improved survival (Bang 2010, Smyth 2016). 
 
33 
6.6.3 Early gastric cancer (EGC) and endoscopic techniques 
EGC is confined to the mucosa or submucosa without lymph node metastases; it is 
more often discovered in Asian countries because of their more comprehensive 
screening programs. When it is more readily identified and treated, survival rates are 
correspondingly much better. Patients with EGC have an even more favorable 
prognosis after radical surgery, and because lymph node metastasis is relatively 
infrequent, less invasive surgery may be practical (Tanizawa 2010). Endoscopic 
resection techniques may be an option for curative treatment for patients with 
intestinal-type cancer less than 2 cm in diameter without submucosal invasion or 
lymph-angio invasion. Risk of lymph-node metastases in this group is minimal 
(Nakajima 2002, Smyth 2016). Careful preoperative staging, correct patient 
selection, and an accurate report by an experienced pathologist are required for 
successful resection. Endoscopically treated patients have shown a disease-specific 
survival at 5 years of more than 95% (Bennett 2009).  
 
The two forms of endoscopic resection are endoscopic mucosal resection (EMR) and 
endoscopic submucosal dissection (ESD). EMR is suitable for lesions smaller than 
10 to 15 mm with a polypoid or elevated form. However, ESD is the treatment of 
choice for most gastric superficial neoplastic lesions by European Society of 
Gastrointestinal Endoscopy Guidelines (Pimentel-Nunes 2015).  
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6.7 Prognostic factors 
6.7.1 TNM classification 
 
The most important factors that determine the prognosis of a patient with gastric 
cancer are radical surgery with adequate lymph-node dissection and stage of the 
disease at diagnosis. The Union for International Cancer Control (UICC)/the 
American Joint Committee on Cancer (AJCC) guidelines and their staging manual’s 
tumor-node-metastasis (TNM) system is the most widely used and accepted staging 
classification system, continously evolving because of periodic validation studies. At 
present, the seventh edition has been in clinical practice (Table 1 and 2, Figure 5) but 
the eighth edition is already published (Sobin 2009, Edge 2010, Brierley 2017). The 





Table 1. TNM classification of gastric cancer. Adapted from TNM Classification of Malignant 
Tumours, 7th Edition (Sobin 2009).  
Primary Tumor (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ: intraepithelial tumor without invasion of the lamina 
propria, high grade dysplasia 
T1 Tumor invades lamina propria, muscularis mucosae (T1a), or 
submucosa (T1b) 
T2 Tumor invades muscularis propria 
T3 Tumor invades subserosa 
T4 Tumor perforates serosa (T4a) or invades adjacent structures (T4b) 
Regional Lymph Nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-2 regional lymph nodes 
N2 Metastasis in 3-6 regional lymph nodes 
N3 Metastasis in 7 or more regional lymph nodes (N3a: 7-15, N3b: 16 or more) 
Distant Metastasis (M) 
M0 No distant metastasis 




Table 2. TNM staging and 5-year survival for surgically resected gastric cancers. Adapted from 
TNM Classification of Malignant Tumours, 7th Edition and AJCC Cancer Staging Manual (Edge 
2010, Sobin 2009). 
 
 
Stage T N M 5-year survival (%) 
0 Tis 0 0   
IA 1 0 0 70.8 
IB 2 0 0 57.4 
  1 1 0   
IIA 3 0 0 45.5 
2 1 0 
  1 2 0   
IIB 4a 0 0 32.8 
3 1 0 
2 2 0 
  1 3 0   
IIIA 4a 1 0 19.8 
3 2 0 
  2 3 0   
IIIB 4b 0,1 0 14.0 
4a 2 0 
  3 3 0   
IIIC 4a 3 0 9.2 
  4b 2,3 0   





Figure 5. The extent of tumor (T) in TNM classification of gastric cancer (Sobin 2009). Figure 
drawn by Marja Ojala.  
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6.7.2  Tumor location and histology 
Proximally located tumors tend to have a worse prognosis than distal tumors. The 
lesser curve of the stomach harbors more gastric cancer tumors than does the greater 
curve. In addition, diffuse-type cancers typically have more peritoneal metastases, 
whereas the intestinal type favors blood-borne metastases. The diffuse type tends to 
develop metastases early and is associated with poor outcome (Laurén 1965, Archie 
2006).  
6.7.3 Biomarkers 
Besides the early detection and primary prevention of gastric cancer, the key to 
improving patient outcome may arise from finding more effective treatments and 
personalizing individual patient treatment based on prognostic and response-
predictive factors such as biomarkers. 
 
In clinical practice, human epidermal growth factor receptor 2 (HER2) is the only 
predictive biomarker for targeted therapy currently used for patient selection in 
gastric cancer. The mean frequency of HER2 overexpression in gastric and 
gastroesophageal cancer is 18%, and it is more common in intestinal type cancer. 
Studies indicate that positive HER2 is a negative prognostic factor, predicting more 
aggressive biological behavior and higher frequencies of recurrence (Tanner 2005, 
Abrahao-Machado 2016). Trastuzumab, a monoclonal antibody direct against HER2, 
was one of the first developed molecular-targeted drugs. It was first introduced for 
the treatment of HER2-positive advanced breast cancer. In HER2-expressing 
unresectable gastric and gastroesophageal cancers, trastuzumab together with 
chemotherapy causes an increase in overall survival compared to chemotherapy 
alone (Bang 2010). 
 
The most extensively studied tumor markers in gastric cancer are serum 
carcinoembryonic antigen (CEA), and carbohydrate antigens 19-9 (CA 19-9) and 72-
4 (CA 72-4). None of them is sensitive enough to stand alone as indicators of the 
presence of the disease or nor does either of them predict survival (Kodera 1996, Lai 
2002, Huang 2014, Shimada 2014). 
6.8 Biomarkers in this thesis 
6.8.1 PODXL 
Podocalyxin (PODXL) is a cell surface transmembrane protein belonging to the 
CD34 family, which is encoded on chromosome 7q32-q33. PODXL was first 
described in kidney podocytes as an anti-adhesive protein. It is a major component 
of the cell coat, glycocalyx of the glomerular podocytes, and thus this molecule was 
called podocalyxin (Kerjaschki 1984). PODXL is also expressed in vascular and 
 
37 
breast endothelium, in hematopoietic progenitors, and it is involved in neural 
development (Horvat 1986, Kerosuo 2004, Somasiri 2004, Vitureira 2010). 
 
PODXL expression, reported in various cancers, has mostly been linked to poor 
prognosis, for example in breast, bladder, pancreatic, colorectal, and esophageal 
cancers, and in glioblastoma multiforme (Somasiri 2004, Larsson 2011,2012, Binder 
2013, Boman 2013, Kaprio 2014, Heby 2015, Saukkonen 2015, Borg 2016). To the 
best of our knowledge, no earlier studies concern PODXL expression in gastric 
cancer. 
 
The role of PODXL in tumorigenesis and cancer is not widely understood. PODXL 
has been thought to promote cancer cell invasion and migration, thus enhancing 
metastatic potential (Lin 2014, Flores-Téllez 2015, Snyder 2015). Other mechanisms 
are PODXL’s evading the immune response by serving as an immunomodulatory 
molecule and maintaining and regulating glucose-transporters’ surface expression 
(Schopperle 2010, Amo 2015). Interestingly, in cell lines of osteosarcoma, PODXL 
has shown resistance to cisplatin, an important cytotoxic drug also used in the 
treatment of gastric cancer (Huang 2015). 
6.8.2 PROX1 
Prospero homeobox protein 1 (PROX1) is a transcription factor that binds DNA and 
promotes transcriptional regulation of other genes. It belongs to a family of 
homeobox transcription factors, and the gene is localized on chromosome 1q32.2–
q32.3. PROX1 protein contains 737 amino acids with a molecular mass of 82.3 kDa 
(Zinovieva 1996, Elsir 2012). PROX1 has appeared as a key regulatory protein in 
neurogenesis and organ development. It is important in embryonic development of 
the lens, retina, liver, pancreas, and lymphatic vasculature; PROX1 knockout mice 
have multiple developmental defects leading them to die before birth (Oliver 1993, 
Wigle 1999, Elsir 2012). 
 
As a transcriptional regulator, varying levels of PROX1 expression have been 
reported in several cancer types, with the role of PROX1 apparently varying from 
tumor-suppressive to oncogenic. PROX1 is able to both activate and inhibit 
transcription of genes, and in many cancers, what is unclear is whether the role of 
PROX1 lies more in tumor initiation or in progression (Abate-Shen 2002, Elsir 
2012).  
 
Varying levels of PROX1 protein occur in various cancers, and its clinical 
significance is controversial depending on the cancer tissue. PROX1 expression has 
been associated with inferior patient outcome and cancer progression in colorectal 
and hepatocellular cancers, and in malignant gliomas (Shimoda 2006, Petrova 2008, 
Elsir 2010, Skog 2011, Liu 2013). Other malignancies that PROX1 is involved in 
included neuroblastoma, breast cancer, pancreatic cancer, esophageal cancer, 
carcinomas of the biliary system, hematologic malignancies, and Kaposi’s sarcoma 
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(Nagai 2003, Schneider 2006, Laerm 2007, Versmold 2007, Yoshimoto 2007, Yoo 
2010, Foskolou 2013, Saukkonen 2016). 
 
In gastric cancer, PROX1 may play a role in tumor progression by enhancing cancer-
cell proliferation and lymphangiogenesis, serving as a potential prognostic factor and 
target for treatment (Park 2017). Park et al. also studied the prognostic role of 
PROX1 in gastric cancer patients by immunohistochemistry, finding that the 
prognosis with PROX1-positive tumors was significantly worse than with negative 
tumors. In addition, dysregulation of microRNAs (miRNAs) are linked to 
tumorigenesis and tumor progression, and miR-489 has been downregulated in 
gastric cancer tissue. PROX1 is a direct miR-489 target serving, for this miR-
489/PROX1 axis, as a potential therapeutic target in gastric cancer (Zhang 2016).  
6.8.3 UCHL5 
In the cell, the proteasome plays an important role in proteostasis by carrying out 
controlled protein degradation. Ubiquitin carboxyl-terminal hydrolase L5 (UCHL5), 
also called ubiquitin C-terminal hydrolase 37 (Uch37), is a cysteine protease 
belonging to the family of ubiquitin C-terminal hydrolases. It is one of three known 
human proteasome-associated deubiquitinating enzymes (DUBs), with a molecular 
mass of 37 kDa; it consists of 329 amino acids (Yao 2006, Jiao 2014). UCHL5 binds 
to its proteasome subunit Admr1/Rpn13 via reversible association, which activates 
its DUB activity (Matilainen 2013, Tian 2014). The function of UCHL5 is crucial, as 
UCHL5 knockout in mice is embryonically lethal (Al-Shami 2010). 
 
In human tissues, expression level and cellular location of UCHL5 vary. It occurs in 
both healthy and cancerous tissues and has been associated with Alzheimer’s disease 
and pulmonary fibrosis (Kikuchi 2013, Nan 2016). Proteasome inhibitors, for 
example bortezomib, serve as therapeutics for refractory multiple myeloma and 
mantle cell lymphoma (Schmidt 2014, Selvaraju 2015). 
 
The ubiquitin-proteasome system, and UCHL5 as a part of it, is linked to cancer 
partly due to its capability to regulate many cell cycle proteins and apoptotic 
molecules (Mani 2005, Kitagawa 2009). High UCHL5 expression associates with 
cancer recurrence and poor survival in esophageal squamous cell, hepatocellular, and 
epithelial ovarian cancers (Chen 2012, Fang 2013, Wang 2014). In contrast, patients 
with high UCHL5 expression in pancreatic ductal adenocarcinoma and lymph-node-
positive rectal cancer tend to have better prognosis (Arpalahti 2017). To the best of 
our knowledge, no studies concerning UCHL5 and gastric cancer exist. 
6.8.4 MMP-8 
Matrix metalloproteinase-8 (MMP-8) is part of the genetically distinct but 
structurally similar family of zinc-dependent metalloendopeptidases. Up to now, 24 
different vertebrate MMPs have been recognized, of which 23 are identified in 
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humans. MMPs play an important role in many biological processes, such as 
embryogenesis, tissue remodeling, wound healing, and angiogenesis. MMPs can be 
classified based on their primary structures and substrate specificities. The key 
feature of MMP-8 enzyme, also called collagenase-2, is its ability to cleave 
interstitial collagens and other molecules. MMP-8 is mainly produced by neutrophils 
and encoded on chromosome 11q21-q22 (Nagase 1999, Egeblad 2002, Visse 2003). 
Elevated MMP-8 levels have been detectable in different inflammatory diseases such 
as periodontitis and H.pylori gastritis, and also in cardiovascular diseases (Sorsa 
2004, Tuomainen 2007, Rautelin 2009, Pradhan-Palikhe 2010). 
 
The extracellular matrix (ECM) of tumors and the non-cancerous, stromal cells 
within tumors also have an effect on tumor progression (Bissell 2001). MMPs have 
an ability to hydrolyze components of the ECM and also significantly to influence in 
all six steps, or hallmarks, of cancer development by promoting the growth and 
survival of cancer cells, regulating invasion by degrading structural ECM, by 
promoting angiogenesis and the epithelial-to-mesenchymal transition (EMT), and by 
inhibiting immune reactions against cancer cells (Hanahan 2000, Egeblad 2002). 
Increased expression of certain MMPs have been detectable in various cancer types, 
and their over-expression is often associated with poor prognosis. Some synthetic 
pharmaceutical MMP inhibitors have been developed for anticancer drugs, but the 
results in clinical trials have been disappointing because of major adverse effects or 
lack of benefits (Egeblad 2002). 
 
The role of MMP-8 in cancer is more complex. MMP-8 may have protective 
properties in cancer through its capability to regulate the inflammatory response 
(Balbín 2003). In tongue cancer, MMP-8 has shown antitumor activity, and in breast 
cancer it may protect against lymph-node metastasis (Decock 2008, Korpi 2008, 
Soria-Valles 2014). In contrast, in hepatocellular carcinoma, in melanoma, and in 
colorectal cancer, increased levels of MMP-8 have been associated with an 
unfavorable course of the disease (Vihinen 2008, Väyrynen 2012, Lempinen 2013). 
6.8.5 TIMP-1 
Tissue inhibitor of metalloproteinase-1 (TIMP-1) is a specific inhibitor that binds 
MMPs in 1:1 stoichiometry. In vertebrates, thus far four different TIMPs have been 
identified, and they are expressed during development and tissue remodeling at 
various levels. TIMP-1 is capable of inhibiting all known MMPs except MT1-MMP, 
and has a crucial function in maintaining a balance between ECM deposition and 
degradation under differing physiological conditions (Will 1996, Gomez 1997, Brew 
2000). When MMP activities are unbalanced under pathological conditions, varying 
levels of TIMPs are considered important, because of their ability to directly affect 
MMP activity levels (Visse 2003).  
 
Despite the major function of TIMP-1 as an inhibitor of MMPs, it takes part in tumor 
invasion and metastasis in a more complex, and sometimes even paradoxical, way. 
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Because overexpression of MMPs is considered to promote tumor progression, it 
would be expected that elevated levels of TIMP-1 would then inhibit this process. 
Paradoxically, several studies, first in colorectal cancer, have associated elevated 
levels of TIMP-1 with the most aggressive tumors and worse prognosis (Urbanski 
1993, Zeng 1995). Investigations have suggested that TIMP-1 may have other 
proteinase-independent activities, including upregulation of anti-apoptotic proteins 
and vascular endothelial growth factors, affecting tumor angiogenesis and direct 
stimulation of cell proliferation (Hayakawa 1992, Yoshiji 1998, Egeblad 2002, Jiang 
2002, Kessenbrock 2010). 
 
High levels of TIMP-1 seem to correlate with poor prognosis in many cancers, so 
TIMP-1 has been under study as a potential prognostic biomarker, for example in 
breast and colon cancers, but it is not yet in clinical use (Egeblad 2002, Schrohl 
2004, Würtz 2008, Birgisson 2010). In gastric cancer, several studies consider 
TIMP-1 as a prognostic biomarker for worse prognosis (Joo 2000, Yoshikawa 2001). 
Grunnet et al. reviewed TIMP-1 in gastric cancer and found 17 articles fulfilling the 
criteria; they concluded that elevated levels of TIMP-1 protein in either tumor tissue 
or in plasma associates with reduced survival in gastric cancer (Grunnet 2013). 
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7 AIMS OF THE STUDY 
The purpose of the study was to evaluate the expression and prognostic significance 
of potential biomarkers in gastric cancer. 
 
The specific aims were to study the prognostic value of 
 
• PODXL immunohistochemical expression in relation to clinicopathological 
parameters by two different antibodies. 
 
• PROX1 immunohistochemical expression in relation to clinicopathological 
parameters. 
 
• UCHL5 immunohistochemical expression in relation to clinicopathological 
parameters. 
 
• MMP-8 serum levels and immunohistochemical expression in relation to 
clinicopathological parameters. 
 





8 PATIENTS AND METHODS 
8.1 Patients (I-IV) 
A total of 650 gastric cancer patients underwent surgery for histologically verified 
gastric adenocarcinoma at the Department of Surgery, Helsinki University Hospital 
between 1983 and 2009. These studies are based on two tissue microarray (TMA) 
series. The first TMA series includes tissue samples from 337 patients operated on 
between 1983 and 1999 and is the material in Study I. The second TMA series 
includes 313 patients operated on from 2000 to 2009 and is the material in Studies II 
and IV. In Study III, both series (650) were combined. 
 
The clinicopathological characteristics of the two study populations are presented in 
Table 3. Overall, 371 (57.1%) were operated on for curative intent, whereas 261 
(40.2%) underwent palliative surgery. Data on cancer resectability was missing in 18 
(2.7%) cases. Extended lymphadenectomy (D2-D2+) was done for 237 (36.5%). 
Preoperative treatment received 15 (2.3%), 157 (24.2%) received post-operative 
adjuvant treatment (101 chemotherapy, 4 radiotherapy, and for 52 both). Median age 
was 66.9 (interquartile range (IQR) 57.0-75.0). Median follow-up time was 1.6 years 
(IQR 0.6-4.7). The 5-year overall survival rate for the whole cohort was 36.2% (95% 
confidence interval (CI) 31.7-40.7%). 
 
Survival data and cause of death for Studies I-IV came from patient records, the 
Population Register Centre of Finland, and Statistics Finland. The studies were 
approved by the Surgical Ethics Committee of Helsinki University Hospital (Dnro 
HUS 226/E6/06, extension TMK02 §66 17.4.2013), and the National Supervisory 
Authority of Welfare and Health gave permission to use the tissue samples without 





Table 3. Clinicopathological characteristics of the two study populations. 
  Study population 1983–1999 Study population 2000–2009 
n (%) 337 313 
Age, years 
< 66 165 (49.0)  148 (47.3) 
≥ 66 172 (51.0) 165 (52.7) 
Gender 
Male 174 (51.6) 152 (48.6) 
Female 163 (48.4) 161 (51.4) 
Stage 
I 100 (29.7) 62 (19.8) 
II 41 (12.2) 72 (23.0) 
III 96 (28.5) 115 (36.7) 
IV 100 (29.7) 63 (20.1) 
Primary tumor, T 
T1 59 (17.5) 49 (15.7) 
T2 61 (18.1) 44 (14.1)  
T3 154 (45.7) 98 (31.3) 
T4 63 (18.7) 122 (39.0) 
Lymph node metastases, N 
N0 152 (45.1) 104 (33.2) 
N1 95 (28.2) 44 (14.1) 
N2 89 (26.4) 72 (23.0) 
N3 82 (26.2) 
Distant metastases, M 
M0 244 (72.4) 250 (79.9) 
M1 93 (27.6) 63 (20.1) 
Laurén classification 
Intestinal 142 (42.1) 124 (39.6) 
Diffuse 195 (57.9) 179 (57.2) 
Tumor size, cm 
< 5 185 (54.9) 115 (36.7) 
≥ 5 146 (43.3) 190 (60.7) 
 
8.2 Tumor tissue specimens (I-IV) 
Formalin-fixed and paraffin-embedded tumor samples were collected from the 
archives of the Department of Pathology, Helsinki University Hospital. The patient 
tissues were de-identified and analyzed anonymously. An experienced pathologist 
marked representative tumor areas for microarrays on hematoxylin- and eosin 
(H&E)-stained slides. In the first TMA series (Studies I and III) three 0.6-mm cores 
and in the second TMA series (Studies II-IV) four 1.0-mm cores were punched with 
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a semiautomatic tissue microarray instrument (Beecher Instruments, Silver Spring, 
MD, USA). The cores were embedded in paraffin as tissue-array blocks (Kononen 
1998). 
8.3 Immunohistochemistry (I-IV) 
The tumor tissue microarrays blocks were freshly cut into 4-µm thick sections, fixed 
on slides, and dried for 12 to 24 hours at 37°C. After deparaffinization in xylene, and 
rehydration through a gradually decreasing concentration of ethanol to distilled 
water, slides were treated in a PreTreatment module (Lab Vision Corp., Fremont, 
CA, USA) in antibody-specific buffer for 20 minutes at 98°C for antigen retrieval. 
Section staining was performed in an Autostainer 480 (Lab Vision) by the Dako 
REAL EnVision Detection system, Peroxidase/DAB+, Rabbit/Mouse (Dako, 
Glostrup, Denmark). Slides were incubated with the chosen antibody for one hour at 
room temperature. For a descriptive list of antibodies used (I-IV) see Table 4. 
 
In Study I, we used two PODXL antibodies against different epitopes. The 
polyclonal antibody (HPA2110, Atlas Antibodies, Stockholm, Sweden) recognizes 
amino acid residues 278–415 of PODXL, and the monoclonal in-house antibody 
HES9 (produced by our collaborators at Fujirebio Diagnostics Ab, Gothenburg, 
Sweden) recognizes the amino acid residues 189–192 of PODXL. Both of these 
epitopes are located in the extracellular part of PODXL (Uhlén 2005, Pontén 2008, 
Kaprio 2014). 
Table 4. Antibodies for immunohistochemistry 
Antibody Company Dilution Control tissue Study 
PODXL HES9 mAb In-house 1:500 Kidney I 
PODXL HPA2110 pAb Atlas Antibodies 1:250 Kidney I 
PROX1 pAb R&D Systems 1:1800 Colon II 
UCHL5 pAb Sigma Aldrich 1:800 Colon III 
MMP-8 pAb In-house 1:400 Colon, breast IV 
Abbreviations: mAb = monoclonal antibody, pAb = polyclonal antibody 
8.4 Scoring of samples (I-IV) 
Tumor specimens were scored independently by two, and in Study III, by three 
researchers blinded to clinical status and outcome data. Samples with discordant 
scores were re-evaluated until consensus. There were three (Studies I and III) or four 
(Studies II-IV) distinct tumor cores per patient, with the highest score of each sample 
serving for further analysis. All antibodies (I-IV) stained mainly cytoplasmic in 
gastric cancer cells, with their intensity of staining graded from 0 to 3. Negative 
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immunoreactivity was scored as 0, weakly positive as 1, moderately positive as 2, 
and strongly positive as 3.  
8.5 Serum samples (IV) 
Blood samples, in total from 233 patients, were collected within 24 days prior to the 
gastric cancer surgery. The majority of the samples (95.7%) were taken within 3 
days (range 0-24 days) before the operation. The blood samples were centrifuged, 
and plasma and serum components stored as aliquots at -80°C until analysis. Serum 
MMP-8 concentrations were determined by time-resolved immunofluorometric 
assay (IFMA) (Medix Biochemica, Espoo, Finland) according to manufacturer’s 
instructions; the detection limit for MMP-8 was 0.08 ng/ml (Tuomainen 2007). 
Serum levels of TIMP-1 were determined with a commercially available enzyme-
linked immunosorbent assay (ELISA) kit according to manufacturer’s instructions 
(Biotrak ELISA System; Amersham Biosciences, Buckinghamshire, UK) with a 
detection limit of 1.25 ng/ml (Lauhio 2016). For the calculation of MMP-8/TIMP-1 
molar ratios, concentrations (ng/ml) were converted to molarities (mol/l) by use of 
the molecular weights of MMP-8 and TIMP-1 (Visse 2003). 
8.6 Statistical analysis (I-IV) 
Immunohistochemical expressions were dichotomized for statistical purposes: 
PODXL, UCHL5, and MMP-8 as negative (score 0) vs. positive (scores 1-3), and 
PROX1 as low (0-1) vs. high (2-3) immunostaining. Associations between various 
immunoexpression and clinicopathological variables were assessed by the chi-square 
and Fisher’s exact tests. Correlations between the two PODXL antibodies (Study I) 
were assessed by Spearman’s correlation test. In Study IV, the Mann-Whitney U-test 
and Kruskal-Wallis test allowed determination of the significance of difference in 
biomarker median serum concentrations among gastric cancer subgroups. For serum 
biomarkers MMP-8 and TIMP-1 and for the MMP-8/TIMP-1 molar ratio (Study IV), 
we determined optimal cut-offs by the aid of receiver-operating characteristic (ROC) 
curves and found them to identify groups suitable for survival analyses. Cancer-
specific survival was calculated from date of surgery to death from gastric cancer or 
until follow-up. Patients who died from causes other than gastric cancer were 
censored at the date of their death. Survival curves were constructed according to the 
Kaplan-Meier method and compared with the log-rank test. Uni- and multivariate 
survival analyses were performed with the Cox proportional hazard model according 
to the backward stepwise method. All statistical tests were two-sided. A p-value 
below 0.05 was considered statistically significant. Statistical analyses were 




9.1 Immunohistochemistry (I-IV) 
The score distribution by the various antibodies studied is presented in Table 5.  
 
In Study I, both PODXL antibodies stained evenly throughout the cytoplasm without 
nuclear nor cell membranous staining. Weak to strongly positive scores (1-3) were 
regarded as positive expression for the following analysis. Expression of PODXL by 
these two different antibodies correlated (rs=0.455, p<0.001, Spearman's rank 
correlation test). 
 
In Study II, cytoplasmic PROX1 expression was negative or weakly positive in 217 
(79.5%) cases and was regarded as low expression for final analysis. The other 
group, high expression, included 56 (20.5%) moderately or strongly positive tumor 
samples. The staining occurred mainly in the cytoplasm, but also, in some strongly 
stained samples, a little nuclear immunopositivity was detectable. 
 
In Study III, cytoplasmic and nuclear UCHL5 staining occurred, but due to an 
overlap in a large number of samples, no separate evaluation of nuclear staining was 
possible. Cytoplasmic UCHL5 expression was negative in 111 (22.7%) and positive 
in 379 (77.3%) samples. 
 
In Study IV, MMP-8 immunoexpression was also cytoplasmic, and neutrophils also 
showed MMP-8 immunopositivity. MMP-8 expression was negative in 157 (56.9%) 
and positive (scores 1-3) in 119 (43.1%) cases. 
 
Table 5. Score distribution of immunohistochemical markers in Studies I-IV. 
Tumor marker Cytoplasmic expression score, n (%) Total 
0 1 2 3   
      
PODXL HES9 67 (24.0) 137 (49.1) 54 (19.4) 21 (7.5) 279 
PODXL HPA2110 113 (42.5) 120 (45.1) 29 (10.9) 4 (1.5) 266 
PROX1 118 (43.2) 99 (36.3) 39 (14.3) 17 (6.2) 273 
UCHL5 111 (22.7) 217 (44.3) 119 (24.3) 43 (8.8) 490 
MMP-8 157 (56.9) 85 (30.8) 30 (10.9) 4 (1.4) 276 
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9.2 Association with clinicopathological characteristics 
(I-IV) 
Associations of different biomarkers with clinicopathologic characteristics were 
analyzed by the chi-square test. 
 
In Study I, positive PODXL staining by both antibodies (HPA2110 and HES9) 
associated with intestinal cancer type (p<0.001 for both). Positive HES9 staining 
also associated with age 66 or over (p=0.001) and with small-sized (≤ 5 cm) tumors 
(p=0.024, Table 6). 
 
In Study II, low PROX1 immunostaining associated with diffuse cancer type 
(p=0.002, Table 6). 
 
In Study III, positive immunostaining of UCHL5 associated with intestinal cancer 
type (p=0.004, Table 6), but not with any other parameters studied. 
 
In Study IV, negative MMP-8 immunoexpression associated with patient under 67 
(p=0.007), stage I cancer (p=0.022), tumor classification T1 (p=0.005), cancer 
without lymph node metastasis (p=0.016), and with diffuse cancer type (p<0.001, 
Table 6). 
 






HES9 PROX1 UCHL5 MMP-8 
Age NS p=0.001 NS NS p=0.007 
Gender NS NS NS NS NS 
TNM stage NS NS NS NS p=0.022 
pT-classification NS NS NS NS p=0.005 
pN-classification NS NS NS NS p=0.016 
pM-classification NS NS NS NS NS 
Laurén classification p<0.001 p<0.001 p=0.002 p=0.004 p<0.001 
Tumor size NS p=0.024 NS NS NS 
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9.3 Serum MMP-8 and TIMP-1 results (IV) 
Median MMP-8 serum level was 54.8 ng/ml (IQR 30.8-105 ng/ml) and for TIMP-1, 
156 ng/ml (IQR 132-187 ng/ml). Median molar ratio of MMP-8/TIMP-1 was 0.153 
(IQR 0.082-0.280). Serum levels of MMP-8 and TIMP-1 were higher in patients 
with the intestinal cancer type (p=0.044, p=0.021, Mann-Whitney U-test). TIMP-1 
serum levels were also higher among patients over age 67 (p<0.001), with 
metastasized disease (p=0.035), and in samples with positive MMP-8 
immunohistochemistry (p=0.008). Moreover, the MMP-8/TIMP-1 molar ratio was 
higher among patients under 67 years (p=0.034, Table 1 in Study IV). 
9.4 Survival analysis (I-IV) 
In Study I, Kaplan-Meier analysis showed significantly worse cancer-specific 
survival for patients with positive PODXL expression. Gastric cancer-specific 5-year 
survival, by polyclonal antibody HPA2110, was 24% (95% CI 16.9-31.1) for 
positive expression, compared to 43% (95% CI 33.7-52.9) for patients with negative 
expression (p=0.001 log-rank test, Figure 6, Table 7). The 5-year survival rate of 
patients with PODXL-positive tumors by monoclonal HES9 antibody was 30% 
(95% CI 23.1-36.1), and with negative expression, 40% (95% CI 27.7-52.1; p=0.130 
log-rank test, Table 7). Positive PODXL was a marker of worse prognosis in the 
subgroups of younger (< 66 years) patients (p=0.006), for men (p=0.002), diffuse 
cancer (p=0.001), and TNM stage I (p=0.048). 
 
In Study II, the gastric cancer-specific survival for patients with high PROX-1 
expression was significantly better than for patients with low immunoexpression. 
The 5-year survival rate for patients with high expression was 65.6% (95% CI 52.7–
78.5), compared to 37.1% (95% CI 30.2–44.0) for patients with low expression 
(p=0.004, log-rank test, Figure 7, Table 7). In subgroup analysis, high PROX1 
expression was a marker of better prognosis in subgroups of younger (< 66 years) 
patients (p=0.007), men (p=0.019), patients with small (< 5 cm) tumors (p=0.030), 
and in the subgroup of intestinal cancer (p=0.025). 
 
In Study III, no significant difference emerged in cumulative survival between 
patients with UCHL5-negative or -positive immunostaing. The 5-year cancer-
specific survival rate for the negative group was 31.3% (95% CI 22.5-40.4), and 
37.7% (95% CI 32.5-42.8) for the positive group (p=0.107, log-rank test, Table 7). 
Positive UCHL5 was a marker of better prognosis in the subgroups of patients aged 
66 or older (p=0.037), in TNM stage I-II (p=0.025), and in patients with small (< 
5cm) tumors (p=0.001). 
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In Study IV, for serum biomarkers MMP-8, TIMP-1, and the MMP-8/TIMP-1 molar 
ratio, we determined optimal cut-offs by the aid of receiver-operating characteristic 
(ROC) curves. The patients with serum MMP-8 lower than 31 ng/ml or over 131 
ng/ml had a prognosis considerably worse than did patients with an intermediate (31-
131 ng/ml) MMP-8 serum level  (p=0.002, log-rank test, Figure 8A). The 5-year 
survival rate for patients with low serum MMP-8 was 29.7% (95% CI 17.2-42.2), 
37.2% (95% CI 21.9-52.5) for high MMP-8 level, and 53.1% (95% CI 44.3-61.9) for 
intermediate level (Table 7). Patients with high (≥ 170 ng/ml) serum TIMP-1 
concentration had a poor prognosis and a 5-year survival rate of 30.6% (95% CI 
20.2-41.0) compared to those of patients with low (<170 ng/ml) level with a 5-year 
survival rate of 52.3% (95% CI 43.9-60.7) (p<0.001, log-rank test, Figure 8B, Table 
7). The molar ratio of serum MMP-8/TIMP-1 had also two cut-offs, and patients 
with a low (< 0.07) or high (> 0.30) molar ratio had a worse prognosis than did those 
with an intermediate ratio (p=0.020, log-rank test, Figure 8C, Table 7). Differences 
in tissue MMP-8 immunoexpression had no significant influence on gastric-cancer-
specific survival of patients (p=0.178, Table 7).  
 
In subgroup analysis, intermediate MMP-8 serum level (31-131 ng/ml) was a marker 
of better prognosis in subgroups of patients aged 67 or over (p=0.015), in men 
(p=0.004), in TNM stages I-II (p=0.003), in pT2 (p<0.001) and pT3 (p=0.011) 
tumors, in lymph-node-positive cancers (p=0.037), in cancers without distant 
metastasis (p<0.001), in both intestinal (p=0.022) and diffuse (p=0.038) cancer, and 
in small (≤ 6 cm) tumors (p=0.001). Patients with low TIMP-1 concentration (< 170 
ng/ml) had a better prognosis in the subgroups of both age categories: < 67 years 
(p=0.012) and ≥ 67 (p=0.038), in both genders: men (p=0.024) and women 
(p=0.003), in stages III-IV (p<0.001), in pT4 tumors (p<0.001), tumors with lymph-
node metastasis (p<0.001), tumors both without (p=0.018) and with (p=0.016) 
distant metastasis, and in both intestinal (p=0.002) and diffuse (p=0.005) type 
cancers, and in both size categories: ≤ 6 cm (p=0.024) and > 6cm (p=0.002). 
Negative tissue immunostaining of MMP-8 was a marker of better prognosis in 
women (p=0.026) and among those with serum MMP-8 lower than 31 ng/ml 
(p=0.018). When MMP-8 immunostainings were analyzed as two subgroups: 
negative and positive, we found that intermediate serum MMP-8 level (31-131 
ng/ml) was a significant marker of better prognosis in both subgroups. In addition, 
low TIMP-1 level (< 170 ng/ml) was a significant marker of better prognosis solely 








Figure 6. PODXL expression with polyclonal HPA2110 antibody and cancer-specific survival 




Figure 7. PROX1 expression and cancer-specific survival according to the Kaplan-Meier method 
p-value for log-rank test.  
Patients at risk
PODXL negative  113             37             28              22             18               7
PODXL positive   150             30             23              19             12               6  
Patients at risk
PROX1 low         217                      67                       29                        5
PROX1 high        56                        29                        9                         2  
52 
 
Figure 8. Serum levels of A) MMP-8, B) TIMP-1, and C) MMP-8/TIMP-1 molar ratio and cancer-
specific survival according to the Kaplan–Meier method, p-value for log-rank test.  
Patients at risk
MMP-8/TIMP-1 <0.07               44                     8                       7                     1
MMP-8/TIMP-1 0.07-0.30        139                   60                     28                    4
MMP-8/TIMP-1 >0.30               50                    21                      7                     1
Patients at risk
TIMP-1 <170 ng/ml                  146                   68                     31                     6
TIMP-1 ≥170 ng/ml                   87                    21                     11                        0
Patients at risk
MMP-8 <31 ng/ml                     60                    13                      8                      1
MMP-8 31-131 ng/ml               133                   62                     31                     5






Table 7. Kaplan-Meier analysis for cancer-specific survival (CSS) stratified for different 
clinicopathological variables and biomarkers in gastric cancer patients; p-value for log-rank test. 
  5-year CSS % 95% CI p-value 
Gender 
Male 46.3 37.7-54.9 0.461 
Female 40.9 33.1-48.7 
Age 
< 67 47.2 39.2-55.2 0.053 
≥ 67 39.3 31.1-47.5 
Stage 
I 93.0 86.3-99.7 <0.001 
II 64.5 52.5-76.5 
III 23.6 15.4-31.8 
IV 5.70 0-12.0 
Laurén classification 
Intestinal 52.0 42.6-61.4 0.020 
Diffuse 37.9 30.7-45.2 
Tumor size 
≤ 6 cm 59.1 51.5-66.7 <0.001 
> 6 cm 21.5 13.9-29.1 
PODXL HPA2110 
Negative 24.0 16.9-31.1 <0.001 
Positive 43.3 33.7-52.9 
PODXL HES9 
Negative 30.0 23.1-36.1 0.130 
Positive 40.0 27.7-52.1 
PROX1 
Low 37.1 30.2-44.0 0.004 
High 65.6 52.7-78.5 
UCHL5 
Negative 31.3 22.5-40.4 0.107 
Positive 37.7 32.5-42.8 
MMP-8 
Negative 46.3 38.1-54.5 0.178 
Positive 36.3 27.1-45.5 
Serum MMP-8 (ng/ml) 
< 31 29.7 17.2-42.2 0.002 
31-131 53.1 44.3-61.9 
> 131 37.2 21.9-52.5 
Serum TIMP-1 (ng/ml) 
< 170 52.3 43.9-60.7 <0.001 
≥ 170 30.6 20.2-41.0 
Serum MMP-8/TIMP-1 molar ratio 
< 0.07 25.5 11.6-39.4 0.020 
0.07-0.30 50.2 41.6-58.8 
> 0.30 45.1 30.8-59.4   
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9.5 Multivariable survival analysis (I-IV) 
Cox regression analysis for different clinicopathological variables and markers 
studied in the study population undergoing surgery between 2000 and 2009 is in 
Table 8. Age, stage, Laurén classification, tumor size, PROX1, and serum TIMP-1 
level served as independent prognostic factors in multivariable survival analysis. 
Separate multivariable models were calculated in each study, utilizing current study 
populations and survival data. 
 
In Study I, PODXL expression of the polyclonal antibody HPA2110 was a 
significant independent prognostic factor (hazard ratio (HR) 3.17, 95% CI 1.37–7.34, 
p=0.007). Other independent factors in multivariable analysis were tumor stage, 
grade, and DNA ploidy. 
 
In Study II, PROX1 expression remained significant (HR 0.56, 95% CI 0.35–0.90, 
p=0.017) in multivariable analysis, together with patient age, metastasized disease, 
and tumor size. 
 
In Study III, UCHL5 expression did not fulfill the Cox assumption of proportional 
hazard ratios over time with all patients included for a multivariable model. 
Nevertheless, UCHL5 expression was a significant prognostic factor in multivariable 
analysis in subgroups of patients at disease stages I-II (HR 0.35, 95% CI 0.19-0.65, 
p=0.001) and in patients with small (< 5 cm) tumors (HR 0.39, 95% CI 0.23-0.66, 
p<0.001). 
 
In Study IV, high TIMP-1 serum level (≥ 170 ng/ml) was an independent prognostic 
factor (HR 1.85, 95% CI 1.26-2.72, p=0.002) in multivariable analysis. Patient age, 
TNM stage, and Laurén classification also served as independent factors. Serum 




Table 8. Cox regression analysis for cancer-specific survival of gastric cancer patients 
undergoing surgery between 2000 and 2009. 
  Univariable survival analysis Multivariable survival analysis 
  HR 95% CI p-value HR 95% CI p-value 
    
Gender     
Male 1.00 1.00 
Female 1.12 0.83-1.50 0.461 1.04 0.70-1.56 0.842 
Age     
< 67 1.00 1.00 
≥ 67 1.33 1.00-1.79 0.054 1.87 1.24-2.81 0.003 
Stage     
I 1.00 1.00 
II 5.44 2.25-13.1 <0.001 4.75 1.57-14.3 0.006 
III 15.7 6.85-36.1 <0.001 15.2 5.38-42.7 <0.001 
IV 46.2 19.6-109 <0.001 60.0 20.1-179 <0.001 
Laurén     
classification     
Intestinal 1.00 1.00 
Diffuse 1.45 1.06-1.98 0.020 1.68 1.09-2.59 0.018 
Tumor size     
≤ 6 cm 1.00 1.00 
> 6 cm 2.71 2.00-3.68 <0.001 1.66 1.10-2.49 0.015 
PROX1     
Low 1.00 1.00 
High 0.52 0.33-0.81 0.004 0.57 0.33-0.96 0.036 
UCHL5     
Negative 1.00 1.00 
Positive 0.69 0.50-0.96 0.027 0.92 0.60-1.41 0.689 
MMP-8     
Negative 1.00 1.00 
Positive 1.24 0.91-1.69 0.179 1.06 0.69-1.61 0.801 
Serum MMP-8     
(ng/ml)     
< 31 1.00 1.00 
31-131 0.56 0.38-0.84 0.004 0.69 0.44-1.09 0.114 
> 131 0.92 0.57-1.48 0.724 1.03 0.59-1.78 0.927 
Serum TIMP-1     
(ng/ml)     
< 170 1.00 1.00 
≥ 170 1.93 1.37-2.72 <0.001 1.71 1.13-2.58 0.011 







To the best of our knowledge, Studies I-IV show for the first time the prognostic 
significance of PODXL, PROX1, UCHL5, and MMP-8 expression in relation to 
clinicopathological variables in gastric cancer. In addition, TIMP-1 has proven to be 




Study I showed PODXL to be an independent marker of unfavorable prognosis in 
gastric cancer, because patients with PODXL-negative tumors survived significantly 
better; actually, among stage-I patients with a PODXL-negative tumor, only one died 
from cancer. After our study, Borg et al. validated this result by also showing that 
PODXL is an independent marker of reduced survival in their TMA series of both 
gastric cancer and esophageal adenocarcinoma (Borg 2016). 
 
The staining of the two antibodies, commercially available polyclonal antibody 
HPA2110 and in-house monoclonal antibody HES9, differed in their intensity. Both 
stained throughout the cytoplasm, but the staining intensity and distribution of the 
monoclonal antibody was stronger than that of the polyclonal antibody. PODXL is a 
transmembrane protein, but this TMA series of gastric cancer showed no staining in 
cell nuclei or cell membranes. The explanation for this cytoplasmic, non-
membranous, expression is unknown. Borg et al. used the same polyclonal antibody, 
and the staining was also mainly in the cytoplasm, sometimes in a granular pattern, 
and they observed some strong membranous component in a few samples (Borg 
2016). Membranous staining has been detectable and has served as a prognostic cut-
off (membranous vs. non-membranous) at least in colorectal and pancreatic cancers 
(Larsson 2012, Heby 2015, Saukkonen 2015). In pancreatic cancer, the staining was 
membranous by both of these same antibodies that we used (Saukkonen 2015). 
 
Results by use of these two antibodies were not identical, and case-by-case 
expressions differed. The antibodies are known to recognize different epitopes in the 
extracellular part of the PODXL molecule, and it is possible that they describe a 
distinct biological phases of PODXL explaining why their results differed in this 
study. Earlier, in colorectal cancer, these same two antibodies revealed an interesting 
finding, in which the polyclonal antibody stained membranously, whereas 
monoclonal antibody positivity was mainly cytoplasmic. Strong positivity of both 
antibodies revealed a subgroup of colorectal cancer patients with even worse 
prognosis (Kaprio 2014). In gastric cancer, we found no similar relationship. The 
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number of positive immunostainings was much higher among colorectal cancer 
patients than in this gastric cancer material (94% vs. 58%). In addition, the PODXL 
positivity in gastric cancer was close to that seen in breast (40%) and ovarian cancer 
(67%), and lower than in the other study, involving gastric cancer (78%) (Somasiri 
2004, Cipollone 2012, Borg 2016). Several reasons could explain this discrepancy, 
for example, an observer-dependent explanation such as setting the cut-off between 
negative and weak-positive staining scores. Further studies should determine optimal 
prognostic cut-offs, which may, of course, differ among cancer types. 
 
The function of PODXL in carcinogenesis is largely unknown. One theory is that 
PODXL enhances cancer cell invasion and migration, and promotes metastatic 
potential. Other theories propose its evasion of natural killer cell-mediated 
cytotoxicity and regulation of glucose transporter surface expression (Schopperle 
2010, Lin 2014, Amo 2015, Flores-Téllez 2015, Snyder 2015). One in vitro study of 
gastric cancer tissues showed that migration and invasion abilities were tightly 
associated with PODXL expression. This offers a promising possibility to design a 
novel target agent that could block PODXL, resulting in inhibition of gastric cancer 
cell migration and invasion (Zhang 2017). In future, we need more research focused 
on the biological role of PODXL in various malignancies. 
 
A recent systematic review and meta-analysis summarized studies related to the 
prognostic significance of PODXL expression among cancers. These 12 studies, 
comprising totally 5309 patients, concluded that high PODXL expression is an 
effective predictor of cancer and could be utilized as a promising prognostic 
biomarker (Wang 2016). 
10.1.2 PROX1 
Study II demonstrated that PROX1 is an independent marker of better prognosis in 
gastric cancer. This was the first study utilizing our new TMA series comprising 
gastric cancer tissue samples from patients operated on between 2000 and 2009 at 
Helsinki University Hospital. This series contains one additional tumor spot and the 
width of each spot is also greater than in our earlier TMA series. 
 
PROX1 expression was visible throughout the cytoplasm, and some nuclear 
positivity was noted in a few strongly stained samples. Other studies have reported 
both cytoplasmic and nuclear immunostaining in gastric cancer (Taban 2014, Park 
2017). Among cancers, staining pattern tends to differ. Nuclear staining is 
observable in colonic and hepatocellular cancers and in gliomas, whereas mainly 
cytoplasmic staining occurs in pancreatic cancer (Shimoda 2006, Elsir 2010, Skog 
2011, Saukkonen 2016). The purpose of cytoplasmic expression is unknown. One 
theory is that PROX1 is enriched and activated in the cytoplasm before its 




As a transcription factor, PROX1 is a key regulatory protein in the development of 
various organs and is involved in many biological processes concerning cell-fate 
determination and progenitor-cell regulation. PROX1 may also exhibit tumor-
suppressive or tumor-promoting effects, depending on tissue context, as is evident in 
several cancers studied. Positive PROX1 expression is associated with favorable 
prognosis, at least in pancreatic and hepatocellular cancers, and in carcinoma of the 
biliary system (Shimoda 2006, Laerm 2007, Saukkonen 2016). However, high 
PROX1 levels are associated in many cancer types with poor patient outcome, for 
example, in colorectal cancer, in rectal neuroendocrine tumors, and in renal cell 
carcinoma (Petrova 2008, Skog 2011, Lv 2014, Jernman 2015). This diversity of 
expression makes PROX1 an interesting and challenging molecule as a potential 
biomarker in cancers. 
 
Few studies have concerned PROX1 in gastric cancer, and the results have been 
interestingly different from ours. Park et al. analyzed PROX1 by silencing its 
expression in gastric cancer cell lines and found this to inhibit cell proliferation. 
They suggested that PROX1 may regulate cell fate by reducing apoptosis as well as 
by promoting proliferation in gastric cancer cell lines. In the same study, they also 
studied the prognostic influence of PROX1 in gastric cancer patient samples by 
immunohistochemistry, finding that positive PROX1 expression associated with 
poor prognosis (Park 2017). Reasons for these contradicting results may be several. 
Their patient material differed from ours, as they did not include metastatic cancer at 
all, the antibodies were not the same, and the staining and scoring methods also 
differed from ours. Zhang et al. studied microRNA, specifically miR-489 in gastric 
cancer tissue and cell lines. They suggest that PROX1 is a direct target for miR-489, 
and PROX1 depletion would then suppress cell proliferation. Based on these 
findings, they hypothesized that low PROX1 expression would correlate with better 
patient prognosis (Zhang 2016). This fascinating discrepancy intrigues researchers 
considering on the role of PROX1 in gastric cancer and its effects on patient 
prognosis. 
10.1.3 UCHL5 
Positive UCHL5 expression revealed better survival in subgroups of stages I-II 
cancer, small tumor size (< 5cm), and age 66 or older. In our whole patient cohort of 
gastric cancer, the difference between positive and negative staining remained 
nonsignificant in survival analysis. 
 
Our immunohistochemical staining pattern was mainly cytoplasmic, with some 
nuclear staining. Because of overlapping of cytoplasmic and nuclear staining in a 
large number of samples, only cytoplasmic staining was evaluated. In other 
immunohistochemical studies, the staining in colorectal cancer, was cytoplasmic, but 
in pancreatic cancer, mainly nuclear (Arpalahti 2017). 
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Earlier, high UCHL5 expression was associated with poor survival and cancer 
recurrence in hepatocellular carcinoma, esophageal cell carcinoma, and epithelial 
ovarian cancer (Chen 2012, Fang 2013, Wang 2014). Our opposite result in gastric 
cancer is more in concordance with results in colorectal and pancreatic cancers 
achieved by a similar immunohistochemical staining method with the same antibody 
(Arpalahti 2017). Reasons for the differences are unknown. Study methods were 
different, for example Western blot in hepatocellular and ovarian cancers, and 
importantly, UCHL5 has high tissue-specificity in expression pattern and may play a 
different role in different cancer tissues. 
 
Several studies have focused on the potential mechanism of UCHL5 in cancer. Thus 
far, UCHL5 and upregulation of transforming growth factor-β (TGF-β) signaling in 
tumors are qite clear (Wicks 2005,2006, Cutts 2011). UCHL5 and TGF-β signaling 
studies have showed that UCHL5-selective knockdown reduces the levels of certain 
TGF-β-dependent target genes, which are vital proteins in promoting tumor 
migration and invasion (Fang 2017). Other potential roles of UCHL5 have been 
studied, for example, by functional proteomic analyses aiming to screen proteins 
interacting with UCHL5 in cancer cells. UCHL5 promotes migration and invasion of 
hepatocellular carcinoma cells (Fang 2013). Thus far, the knowledge of the effects of 
UCHL5 in cancer is limited. Additional studies will lead to understanding of the 
deeper mechanism behind the effects of UCHL5 in cancer. 
10.1.4 MMP-8 and TIMP-1 
Gastric cancer patients with either low or high preoperative serum MMP-8 had a 
significantly more unfavorable prognosis. This study also showed that elevated 
serum TIMP-1 level serves as an independent marker of poor prognosis, as earlier 
demonstrated. Knowing how these two, MMP-8 and TIMP-1, interact with each 
other, it was interesting to calculate the molar ratio of these two molecules. Patients 
with low or high MMP-8/TIMP-1 molar ratios had a considerably worse prognosis. 
We also studied tissue MMP-8 by immunohistochemistry but found it to have no 
influence on gastric cancer prognosis. 
 
Traditionally, tumor markers have used only one cut-off, separating the patients into 
those with good or with poor prognosis. Otherwise, some linear model would show 
what happens to survival when concentration of tumor marker changes. Our 
nonlinear serum MMP-8 results indicate a need for a physiological balance of MMP-
8. A physiological level of MMP-8 is most favorable for the patient with gastric 
cancer, because as either excess or lack of MMP-8 favors cancer aggressiveness. 
 
MMP-8 is an intriguing molecule with its immunoregulating and also antitumor 
properties. Its role in cancer has not been studied extensively. MMP-8 substrates 
include collagen, protease inhibitors, proteases, growth factors, cell-adhesion 
proteins, and cytokines, and it is expressed by a wide range of different cells, for 
example, neutrophils, macrophages, and plasma cells (Van Lint 2006, López-Otín 
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2009). Based on this knowledge that MMP-8 takes part in many biological 
processes, its antitumor properties do not cause surprise. As MMP-8 has an ability to 
modulate tumor cell adhesion and invasion and participate in inflammatory mediator 
processing, MMP-8-deficient mice can develop skin tumors and tongue cancer more 
often than do wild-type mice (Balbín 2003, Gutiérrez-Fernández 2008, Korpi 2008). 
In breast-cancer cells, MMP-8 expression causes a decrease in tumor growth and 
lung metastasis formation, providing evidence of MMP-8 antitumor function in 
cancer and metastasis (Soria-Valles 2014). Korpi et al. showed also that in a clinical 
tongue-cancer patient cohort, MMP-8 expression is significantly associated with 
better survival (Korpi 2008). However, the opposite findings exist, as with elevated 
MMP-8 expression is also linked to advanced cancer type and poor patient outcome 
in hepatocellular carcinoma, in colorectal cancer, and in ovarian cancer (Stadlmann 
2003, Väyrynen 2012, Lempinen 2013). This phenomenon, that patients with 
intermediate MMP-8 survive best, has not yet been described. The role of MMP-8 in 
gastric cancer seems more complex than that of other MMPs. 
 
Unexpectedly, tissue MMP-8, studied by immunohistochemistry, had no effect on 
patient survival. MMP-8 immunostaining was mainly cytoplasmic, and neutrophils 
showed MMP-8 immunopositivity, as well.  Approximately half the samples were 
negative (57%). MMP-8 immunoexpression in malignant diseases has been studied 
to a lesser extent, but the cytoplasmic staining pattern tended to be similar, at least in 
ovarian and colorectal cancers (Stadlmann 2003, Väyrynen 2012). This result shows 
that the same biomarker’s serum level and tissue expression do not necessarily 
correlate, as would have been expected. Peripheral blood MMP levels are thought to 
reflect local MMP concentrations in the tumor microenvironment, but differences 
appear in tumor tissue expression and amounts of active MMP-8 in the circulation. 
The active serum MMP-8 we detected may also originate from different sources 
related to cancer, such as from stroma, rather than from the tumor cells. 
 
High TIMP-1 level predicted worse prognosis as expected on the basis of earlier 
studies (Joo 2000, Yoshikawa 2001, Wang 2006, Mroczko 2009, Kemik 2011, 
Grunnet 2013). TIMP-1 is one of the naturally occurring inhibitors of MMPs, and 
the balance between expression of MMPs and TIMPs during tumor progression is 
interesting. High TIMP-1 level would thus associate with tumor progression and 
unfavorable patient outcome, but would not cause it (Egeblad 2002). However, 
TIMP-1 tends to have also an independent role in cancer progression by its ability to 
inhibit apoptosis, to induce angiogenesis, and to stimulate cell proliferation (Yoshiji 
1998, Jiang 2001,2002, Egeblad 2002, Liu 2005, Kessenbrock 2010). These 
independent effects may lead to cancer cell spread and cause metastasized disease. 
 
TIMP-1 is a biomarker evaluated mostly for prognostics, but also for a predictive 
and diagnostic purpose in a few cases (Grunnet 2013). In gastric cancer, reports 
concerning serum levels of TIMP-1 show elevated TIMP-1 levels to associate with 
poor prognosis (Wang 2006, Mroczko 2009, Kemik 2011). One earlier study showed 
the prognostic value of tissue TIMP-1 as an independent factor of poor prognosis 
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(Mimori 1997). Apart from that, only one study, used disease-specific survival as an 
endpoint when calculating survival, as we did (Joo 2000). Based on these, this study 
strengthens knowledge of TIMP-1 as an independent prognostic biomarker in gastric 
cancer. 
 
TIMP-1 binds MMPs in a 1:1 stoichiometry, and we calculated the molar ratio of 
these two molecules, as we already had measured the serum levels of both. We 
found two cut-offs for MMP-8/TIMP-1 molar ratio, and patients with a low or high 
molar ratio had worse prognosis than did those with an intermediate ratio, as 
expected after the nonlinear MMP-8 result. 
10.2 Strengths and limitations of study materials and 
methods 
The study material consists of two TMA series collected from tumor tissue samples 
from patients operated on during a period of 26 years (1983 to 1999 and 2000 to 
2009). During these years, TNM classification, surgical techniques, and oncological 
treatments have, of course, developed. Based on this, one aim of this thesis project 
was to construct the later TMA series, collect the needed patient data, and apply it to 
biomarker studies. During this project, survival data and cause of death have been 
updated regularly. Thus one notable strength of this work is its large and well-
characterized patient cohort with reliable and long clinical follow-up and survival 
data. 
 
Oncological treatment of gastric cancer has changed greatly. Nowadays, guidelines 
recommend perioperative (pre- and postoperative) chemotherapy for patients with 
resectable  (≥ stage IB) gastric cancer (Smyth 2016). This implies effects from 
chemotherapy already evident in surgical tumor-tissue samples. The behavior of 
antibodies in this kind of tissue may differ from that in untreated tissue. In the first 
TMA series, none of the patients, and in the later series only 15 patients (2.3%) 
received preoperative therapy; we did not exclude those. 
 
The TMA technique, used in all four studies, is suitable to analyze large patient 
cohorts with a homogenous staining method, but allows analysis of only a small 
portion of each tumor. When considering tumor heterogeneity and the surrounding 
stroma, this could cause misinterpretation. With adequate sampling of at least three 
histologically representative spots, the TMA method allows results in concordance 




10.3 Future prospects 
None of the biomarkers studied in this thesis have sufficient evidence to support 
clinical practice as yet. More studies should examine the markers’ behavior in 
healthy and malignant tissues as well as ways to finally apply that information to 
clinical practice and for the benefit of patients. Some fascinating specific questions 
for future prospects arose in the writing of this thesis. 
 
PODXL would also provide promising help as a diagnostic tool. It would be 
interesting to investigate whether serum PODXL would also prove useful in the 
diagnosis of gastric cancer as it is in pancreatic cancer. One recent study showed that 
actually serum levels of PODXL were higher in pancreatic cancer patients than in 
healthy controls, and the authors suggest that increased expression of serum PODXL 
is more accurate for the diagnosis of pancreatic cancer than serum CA19-9 (Taniuchi 
2018). 
 
Both tissue- and blood biomarkers should ideally predict the effect of an oncological 
treatment such as KRAS and cetuximab in colorectal cancer, as well as HER-2 and 
tratszumab in breast and gastric cancers (Ross 2003, Lièvre 2008, Okines 2012). In 
addition to the prognostic value of TIMP-1, it has been studied also as a promising 
biomarker to predict its effect on chemotherapy. In breast cancer, what has been 
shown is that low TIMP-1 is associated with better response to antracycline-based 
chemotherapy (Ejlertsen 2010). In colorectal cancer, TIMP-1 plasma levels are 
associated with response to treatment and with survival benefit when treatment is 
with irinotecan and 5-fluorourasil, but not when 5-fluorourasil is combined with 
oxaliplatin (Sørensen 2007, Frederiksen 2011). These chemotherapy agents are 
treatment options also for gastric cancer; similar studies would thus be interesting 
and useful in gastric cancer as well. 
 
Studies comparing expression of certain biomarkers and differences between their 
tissue and blood levels would be beneficial. Discrepancies can be notable, as we 
noticed with MMP-8. For example, in colorectal and breast cancers, no correlation 
exists between plasma or serum levels of TIMP-1 when compared to their tissue 
levels (Schrohl 2008, Sørensen 2008). These reports suggest that cancer-related 
factors other than only marker concentration in tissue may influence its level in 
plasma or serum.  
 
The use of different combinations or even larger panels of biomarkers would 
enhance their reliability and value. One proposal is to combine the promising new 
markers with ones already in clinical practice, as a Danish study found that when 
combining plasma TIMP-1 and CEA protein measurements; that combination was 






• PODXL expression in tumor tissue is an independent marker in gastric 
cancer of poor prognosis. 
 
• High cytoplasmic PROX1 tumor expression is an independent marker in 
gastric cancer of better prognosis. 
 
• In subgroups of stage I-II, small (< 5 cm) tumor size, and age 66 or older, 
cytoplasmic UCHL5 expression in tumor tissue is linked to better gastric 
cancer prognosis.  
 
• Patients with either low or high preoperative serum MMP-8 have a 
significantly unfavorable gastric cancer prognosis. 
 
• High preoperative serum TIMP-1 is an independent prognostic factor of 
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